JP2019516722A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019516722A5 JP2019516722A5 JP2018560617A JP2018560617A JP2019516722A5 JP 2019516722 A5 JP2019516722 A5 JP 2019516722A5 JP 2018560617 A JP2018560617 A JP 2018560617A JP 2018560617 A JP2018560617 A JP 2018560617A JP 2019516722 A5 JP2019516722 A5 JP 2019516722A5
- Authority
- JP
- Japan
- Prior art keywords
- trigeminal
- painful
- trigeminal neuralgia
- general formula
- neuropathy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000020049 trigeminal nerve disease Diseases 0.000 claims 23
- 206010044652 trigeminal neuralgia Diseases 0.000 claims 21
- 239000003814 drug Substances 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 125000000217 alkyl group Chemical group 0.000 claims 9
- 229940079593 drug Drugs 0.000 claims 9
- -1 carbamate compound Chemical class 0.000 claims 7
- 208000007514 Herpes zoster Diseases 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 150000002431 hydrogen Chemical class 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 125000006731 (C1-C8) thioalkoxy group Chemical group 0.000 claims 3
- 206010016059 Facial pain Diseases 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 3
- 230000001154 acute effect Effects 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000014674 injury Diseases 0.000 claims 3
- 230000003902 lesion Effects 0.000 claims 3
- 201000006417 multiple sclerosis Diseases 0.000 claims 3
- 230000002085 persistent effect Effects 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- 230000008733 trauma Effects 0.000 claims 3
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 claims 2
- 125000004494 ethyl ester group Chemical group 0.000 claims 2
- 238000007918 intramuscular administration Methods 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 238000007920 subcutaneous administration Methods 0.000 claims 2
- KJAMZCVTJDTESW-UHFFFAOYSA-N tiracizine Chemical compound C1CC2=CC=CC=C2N(C(=O)CN(C)C)C2=CC(NC(=O)OCC)=CC=C21 KJAMZCVTJDTESW-UHFFFAOYSA-N 0.000 claims 2
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 claims 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20160061386 | 2016-05-19 | ||
| KR10-2016-0061386 | 2016-05-19 | ||
| PCT/KR2017/005172 WO2017200317A1 (ko) | 2016-05-19 | 2017-05-18 | 삼차신경통을 예방 또는 치료하기 위한 카바메이트 화합물의 용도 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019516722A JP2019516722A (ja) | 2019-06-20 |
| JP2019516722A5 true JP2019516722A5 (enExample) | 2020-07-02 |
| JP6960415B2 JP6960415B2 (ja) | 2021-11-05 |
Family
ID=60325324
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018560617A Active JP6960415B2 (ja) | 2016-05-19 | 2017-05-18 | 三叉神経痛を予防又は治療する目的のためのカルバメート化合物の使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11207295B2 (enExample) |
| EP (1) | EP3459542B1 (enExample) |
| JP (1) | JP6960415B2 (enExample) |
| KR (1) | KR102421013B1 (enExample) |
| CN (1) | CN109310669B (enExample) |
| AU (1) | AU2017267160B2 (enExample) |
| CA (1) | CA3024284C (enExample) |
| DK (1) | DK3459542T3 (enExample) |
| ES (1) | ES2887338T3 (enExample) |
| MX (1) | MX389613B (enExample) |
| PL (1) | PL3459542T3 (enExample) |
| PT (1) | PT3459542T (enExample) |
| RU (1) | RU2751504C2 (enExample) |
| WO (1) | WO2017200317A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11147798B2 (en) | 2016-12-14 | 2021-10-19 | Sk Biopharmaceuticals Co., Ltd. | Use of carbamate compound for prevention, alleviation, or treatment of demyelinating disease |
| ES2978226T3 (es) * | 2018-09-21 | 2024-09-09 | Sk Biopharmaceuticals Co Ltd | Compuesto de carbamato y uso de la formulación que lo comprende para prevenir, aliviar o tratar el trastorno de estrés agudo o el trastorno de estrés postraumático |
| US12465591B2 (en) | 2018-10-19 | 2025-11-11 | Sk Biopharmaceuticals Co., Ltd. | Use of carbamate compound for preventing, alleviating or treating diabetic peripheral neuropathy or chemotherapy-induced peripheral neuropathy |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3415840A (en) | 1965-10-22 | 1968-12-10 | American Home Prod | Pyrazole-1-ethanol derivatives |
| DE2628420A1 (de) * | 1976-06-24 | 1978-01-05 | Bayer Ag | 1-acyloxy-2-imidazolyl-1-phenyl- aethane, verfahren zu ihrer herstellung sowie ihre verwendung als fungizide und nematizide |
| JP2002515050A (ja) * | 1996-12-31 | 2002-05-21 | ジーピーアイ エヌアイエル ホールディングス インコーポレイテッド | ヘテロ環式チオエステルのｎ−結合尿素およびカルバメート |
| BR0207673A (pt) * | 2001-02-27 | 2004-12-28 | Ortho Mcneil Pharm Inc | Compostos de carbamato para o uso no tratamento de dor |
| US7598279B2 (en) | 2005-04-22 | 2009-10-06 | Sk Holdings Co., Ltd. | Neurotherapeutic azole compounds |
| JP4227121B2 (ja) | 2005-06-08 | 2009-02-18 | 独立行政法人科学技術振興機構 | 神経因性疼痛治療剤 |
| US8501436B2 (en) * | 2009-06-22 | 2013-08-06 | Sk Biopharmaceuticals Co. Ltd. | Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester |
| US8404461B2 (en) * | 2009-10-15 | 2013-03-26 | SK Biopharmaceutical Co. Ltd. | Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester |
| EA201300558A1 (ru) * | 2010-11-11 | 2013-11-29 | Акрон Моликьюлис Гмбх | Соединения и способы для купирования боли |
| RU2695607C2 (ru) | 2014-05-09 | 2019-07-24 | Текнимеди Сосьедади Текнику-Медисинал С.А. | (r)-пирлиндол и его фармацевтически приемлемые соли для применения в медицине |
-
2017
- 2017-05-16 KR KR1020170060713A patent/KR102421013B1/ko active Active
- 2017-05-18 CA CA3024284A patent/CA3024284C/en active Active
- 2017-05-18 EP EP17799674.1A patent/EP3459542B1/en active Active
- 2017-05-18 US US16/302,860 patent/US11207295B2/en active Active
- 2017-05-18 PT PT177996741T patent/PT3459542T/pt unknown
- 2017-05-18 CN CN201780030912.5A patent/CN109310669B/zh active Active
- 2017-05-18 PL PL17799674T patent/PL3459542T3/pl unknown
- 2017-05-18 AU AU2017267160A patent/AU2017267160B2/en active Active
- 2017-05-18 DK DK17799674.1T patent/DK3459542T3/da active
- 2017-05-18 WO PCT/KR2017/005172 patent/WO2017200317A1/ko not_active Ceased
- 2017-05-18 MX MX2018014081A patent/MX389613B/es unknown
- 2017-05-18 JP JP2018560617A patent/JP6960415B2/ja active Active
- 2017-05-18 RU RU2018144784A patent/RU2751504C2/ru active
- 2017-05-18 ES ES17799674T patent/ES2887338T3/es active Active
-
2021
- 2021-12-02 US US17/457,308 patent/US20220087976A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020519661A5 (enExample) | ||
| JP2012525393A5 (enExample) | ||
| JP2016512531A5 (enExample) | ||
| RU2015143610A (ru) | Лечение катаплексии | |
| JP2013525318A5 (enExample) | ||
| JP2009504763A5 (enExample) | ||
| JP2015532295A5 (enExample) | ||
| JP2016534063A5 (enExample) | ||
| JP2019521988A5 (enExample) | ||
| JP2019516707A5 (enExample) | ||
| JP2018524298A5 (enExample) | ||
| RU2009102278A (ru) | Модуляторы рецептора s1p для лечения рассеянного склероза | |
| JP2014526503A5 (enExample) | ||
| JP2017141277A5 (enExample) | ||
| RU2019141734A (ru) | Терапевтические соединения и композиции и способы их применения | |
| JP2019516739A5 (enExample) | ||
| JPWO2023099592A5 (enExample) | ||
| JP2019516722A5 (enExample) | ||
| JP2019516726A5 (enExample) | ||
| JP2011518168A5 (enExample) | ||
| RU2011147186A (ru) | 2, 5-дизамещенные арилсульфонамидные антагонисты ссr3 | |
| JP2021506794A5 (enExample) | ||
| RU2015126104A (ru) | Производные аминоциклобутана, способ их получения и их применение в качестве лекарственных средств | |
| JP2016537432A5 (enExample) | ||
| JP2021503451A5 (enExample) |